{"product_id":"xers-five-forces","title":"(XERS) Xeris Biopharma Holdings, Inc. Porters Five Forces Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Xeris Biopharma Holdings, Inc. Porter's Five Forces Analysis helps you assess the company’s competitive environment, including rivalry, buyer and supplier power, substitutes, and new entrants. The page already shows a real preview of the report content, so you can see the style before buying. Purchase the full version for the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSuppliers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized API sourcing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. relies on specialized APIs and high-grade excipients for its 3 marketed products, so qualified suppliers are often few. That raises supplier leverage, especially for niche injectable and liquid drugs where changing sources can trigger revalidation work. Any disruption can delay supply, hurt product availability, and create FDA compliance risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCustom formulation inputs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. relies on 2 proprietary platforms, XeriSol and XeriJect, so it may need specialized excipients, devices, and sterile-process inputs. That shrinks the vendor pool and raises switching costs. If a critical component is single-sourced, suppliers can win pricing and contract leverage, especially when the formulation must stay tightly matched to approved specs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and fill-finish dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. likely faces high supplier power if it relies on third-party sterile makers for fill-finish, packaging, and batch release. Those vendors can delay lots, raise costs, and shape launch timing, especially when sterile capacity is tight. In biopharma, limited specialized capacity makes switching hard, so supplier leverage stays strong.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eQuality and regulatory constraints\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eQuality and regulatory constraints make supplier power high for Xeris Biopharma Holdings, Inc. In pharmaceuticals, approved suppliers must clear audits, GMP controls, and full traceability, and switching them can take months of re-validation. That gives compliant suppliers more leverage than in most industries, especially for critical materials and contract services.\u003c\/p\u003e\n\u003cp\u003eFor context, the FDA received over 4,700 drug and biologic applications in 2025, and each change in a qualified source can trigger new documentation and review. So once a supplier is on the approved list, Xeris Biopharma Holdings, Inc. faces higher cost and delay risk if it tries to replace it.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStrict audits raise supplier power\u003c\/li\u003e\n\u003cli\u003eSwitching needs re-qualification\u003c\/li\u003e\n\u003cli\u003eRegulatory change adds time and cost\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eModerate overall supplier leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. faces moderate to high supplier leverage because drug-grade inputs and specialized services sit with a limited set of approved vendors. It can diversify some noncritical inputs over time, but regulated sourcing and quality controls keep switching costly. The force is not low, since supply disruptions can hit production and launch timing fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eApproved vendors limit switching speed\u003c\/li\u003e\n\u003cli\u003eDrug-grade inputs stay concentrated\u003c\/li\u003e\n\u003cli\u003eRegulated supply chains raise dependence\u003c\/li\u003e\n\u003cli\u003eSupplier power is moderate to high\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier Power Stays High for Xeris Biopharma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. faces moderate to high supplier power because FDA-qualified APIs, excipients, and sterile-fill services are limited and hard to replace. Switching suppliers can trigger re-validation, delays, and added cost. With 2025 FDA drug and biologic applications above 4,700, compliant capacity stays tight. That keeps vendor leverage elevated.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQualified suppliers\u003c\/td\u003e\n\u003ctd\u003eLimited\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwitching time\u003c\/td\u003e\n\u003ctd\u003eMonths\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA apps, 2025\u003c\/td\u003e\n\u003ctd\u003e4,700+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eTailored to Xeris Biopharma Holdings, Inc., this analysis gauges supplier, buyer, substitute, rivalry, and entry pressures shaping profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuickly spot Xeris Biopharma’s competitive pressures in one clean Five Forces view—ideal for fast strategy decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a traceable source trail for Xeris Biopharma, boosting credibility and helping investors verify key assumptions fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacy and distributor concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris sells through a concentrated channel: the top 3 U.S. drug wholesalers handle about 90% of distribution, so a few buyers can influence access and terms. That gives large pharmacies and intermediaries real leverage on rebates, fees, and service levels. Because they control patient flow, Xeris has less room to push price and must protect reimbursement and stocking access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer influence on uptake\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInsurers, PBMs, and government plans drive Xeris Biopharma Holdings, Inc. uptake: PBMs manage about 93% of U.S. prescription claims, and Medicare Part D covers roughly 53 million people. So even if clinicians want a Xeris product, prior auth and formulary status can block fills, making payer power stronger than patient demand alone.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited but important patient choice\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatient choice is limited but still matters. In 2025, Xeris Biopharma Holdings, Inc. sold 3 prescription products: Gvoke, Recorlev, and Keveyis, but severe hypoglycemia, Cushing’s syndrome, and periodic paralysis are physician-led markets, so doctors and reimbursement rules drive most decisions. That cuts end-user bargaining power, though access and copays still influence uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBrand and clinical value support pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. can soften customer pricing power when products save prep time and support cleaner dosing. In 2024, net product revenue was $205.7 million, and branded therapies like Gvoke and Recorlev help defend formulary access by adding clinical value beyond simple price cuts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReady-to-use design weakens price pressure.\u003c\/li\u003e\n\u003cli\u003eClinical value helps formulary placement.\u003c\/li\u003e\n\u003cli\u003eDifferentiation lowers churn risk.\u003c\/li\u003e\n\u003cli\u003eMargins hold better with buyer concentration.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eModerate to high customer power\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. faces moderate to high customer power because large U.S. payers, PBMs, and channel partners control access, coverage, and reimbursement. In biopharma, if a product is not on formulary or gets weak coverage, prescription volume can slow fast, so buyers hold real leverage.\u003c\/p\u003e\n\u003cp\u003eThat means Xeris Biopharma Holdings, Inc. has to win access terms and defend pricing just to keep growth moving. The pressure is strongest in specialty drugs, where a small number of national payers can influence a big share of covered lives.\u003c\/p\u003e\n\u003cp\u003eSo customer bargaining power stays high enough to affect margins, launch speed, and sales force focus, even when clinical demand is solid.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge payers set coverage terms.\u003c\/li\u003e\n\u003cli\u003ePBMs can steer prescriptions.\u003c\/li\u003e\n\u003cli\u003eAccess gaps can slow growth.\u003c\/li\u003e\n\u003cli\u003eReimbursement drives net sales.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXeris Faces Heavy Payer and Wholesaler Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. faces moderate to high customer power: the top 3 U.S. drug wholesalers handle about 90% of distribution, and PBMs manage about 93% of prescription claims. In 2025, the company sold 3 products, so payer access and formulary status can still slow fills and pressure pricing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eKey lever\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesaler concentration\u003c\/td\u003e\n\u003ctd\u003eTop 3 handle about 90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBM control\u003c\/td\u003e\n\u003ctd\u003eAbout 93% of claims\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 portfolio\u003c\/td\u003e\n\u003ctd\u003e3 products\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eXeris Biopharma Holdings, Inc. Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Xeris Biopharma Holdings, Inc. Porter's Five Forces Analysis you’ll receive after purchase—no mockups, no placeholders. It’s the same professionally written, ready-to-use document, fully formatted for immediate download. Once you complete your order, you’ll get instant access to this exact file.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eRivalry Among Competitors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBranded specialty drug competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris competes in 3 branded specialty franchises, and each one faces branded drugs, generics, or treatment alternatives. Rivalry is sharp because access depends on formulary placement and physician preference, not just clinical fit. With a small commercial base, even modest share shifts can move revenue fast, so pricing and payer wins matter.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDefensive product positioning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGvoke, Keveyis, and Recorlev each target focused niches, so direct overlap is limited. Still, Xeris Biopharma Holdings, Inc. competes for the same prescriber time against injectable convenience, endocrine, and rare-disease peers, and it now markets 3 core brands across 3 distinct channels. Differentiation helps, but steady promotion and education still drive share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePipeline-based competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. faces pipeline-based rivalry because it must defend current sales while proving the next wave of products can win too. Larger pharma and biotech rivals can target adjacent indications or build better formulations, so Xeris has to keep improving and protect first-mover gains. That makes innovation pace a real competitive moat test, not just a sales race.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSalesforce and medical education intensity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRivalry is high because Xeris Biopharma Holdings, Inc. competes in specialty drugs, where winning takes more than a good molecule. Heavy salesforce spending, patient support, and physician education can shift share fast, so firms with bigger commercial reach can outpace smaller rivals.\u003c\/p\u003e\n\u003cp\u003eThis makes medical education intensity a real cost and a real moat at the same time. In Xeris Biopharma Holdings, Inc.'s niche, competitors that fund more reps, nurse support, and payer outreach usually get faster uptake and better refill rates.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCommercial scale can beat product quality alone.\u003c\/li\u003e\n\u003cli\u003eField teams and education drive faster share gains.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eModerate competitive rivalry overall\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. faces moderate rivalry because its three marketed therapies are niche, so it avoids pure commodity-style price wars. Still, Gvoke, Recorlev, and Keveyis compete against older therapies, payer step-edits, and larger rivals that can fund faster label expansion and marketing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNiche products reduce direct price wars\u003c\/li\u003e\n\u003cli\u003ePayers still pressure access and pricing\u003c\/li\u003e\n\u003cli\u003eLarger rivals can move faster\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXeris Faces High Rivalry Across Its 3 Niche Franchises\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompetitive rivalry is high for Xeris Biopharma Holdings, Inc. because its 3 branded franchises face older drugs, payer step-edits, and larger specialty peers. Gvoke, Keveyis, and Recorlev are niche, so direct price wars are limited, but formulary wins, prescriber time, and field support still decide share.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBranded franchises\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore channels\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRivalry level\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSubstitutes Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlternative therapies for hypoglycemia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGvoke faces substitute pressure from other glucagon products, oral glucose, and emergency care protocols. For mild episodes, 15-20 grams of fast-acting glucose can work if the patient is awake, so rescue drugs are not always needed. The risk rises when caregivers prefer cheaper, familiar options or when convenience is less important than price and training.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOther treatments for Cushing’s syndrome\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecorlev faces a real substitute threat because Cushing’s syndrome can also be treated with surgery, radiation, or other cortisol-lowering drugs. In a rare disease with about 2 to 3 new cases per 1 million people each year, physicians often tailor care to tumor size, severity, and surgical fit. So if a patient can get surgery or another medical therapy, Xeris Biopharma Holdings, Inc. can lose the sale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompeting approaches in periodic paralysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKeveyis faces meaningful substitution from off-label supportive care, lifestyle changes, and electrolyte or symptom-directed treatment. In periodic paralysis, a rare disorder with highly variable presentation, clinicians often tailor care differently, so some patients are managed without the branded drug. That makes the substitute threat real, even though Keveyis is the only FDA-approved therapy for primary periodic paralysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon-drug and procedural alternatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. faces steady substitute pressure because some endocrine and gastroenterology patients can choose surgery, diet changes, or procedural care instead of drugs. Weight-loss diet plans can reduce body weight by about 5% to 10%, and that can lower medication need in some patients. As disease severity and comorbidities change, the treatment mix can shift away from chronic therapy.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDiet and procedures can replace drugs\u003c\/li\u003e\n\u003cli\u003eDemand shifts with comorbidities and severity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eModerate threat of substitutes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXeris faces a moderate substitute threat because its therapies treat serious, niche conditions, but rivals can still offer alternatives, like standard glucagon rescue, off-label care, or non-drug management. In 2025, Xeris reported revenue of about $245 million, showing demand, yet payer and clinician switching can still pressure use if cheaper options work.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSerious needs support pricing power\u003c\/li\u003e\n\u003cli\u003eAlternatives still exist in each area\u003c\/li\u003e\n\u003cli\u003eSwitching risk keeps threat moderate\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXeris Faces Moderate Substitute Pressure Across Key Drugs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. faces a moderate threat of substitutes because Gvoke, Recorlev, and Keveyis each have clear alternatives, from oral glucose and emergency care to surgery, radiation, off-label care, and supportive treatment. The risk is highest when patients or payers can choose cheaper, familiar, or non-drug options. In 2025, Xeris Biopharma Holdings, Inc. reported about $245 million in revenue, but substitute pressure can still limit pricing power.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDrug\u003c\/th\u003e\n\u003cth\u003eMain substitutes\u003c\/th\u003e\n\u003cth\u003eThreat\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGvoke\u003c\/td\u003e\n\u003ctd\u003eOral glucose, emergency care\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecorlev\u003c\/td\u003e\n\u003ctd\u003eSurgery, radiation, other drugs\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKeveyis\u003c\/td\u003e\n\u003ctd\u003eOff-label and supportive care\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEntrants Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh regulatory barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh regulatory barriers keep new entrants out: drug makers must clear FDA review, cGMP quality systems, and post-marketing pharmacovigilance before scaling. In 2025, the FDA approved 50 new drugs, showing how selective the path is. For Xeris Biopharma Holdings, Inc., that means long timelines, heavy spend, and higher failure risk.\u003c\/p\u003e\n\u003cp\u003eClinical development alone can take 6-10 years, and late-stage programs often cost over $1 billion. Those costs make entry expensive, while quality and safety compliance keep ongoing fixed costs high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital-intensive development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCapital-intensive development keeps the threat of new entrants low for Xeris Biopharma Holdings, Inc. Bringing one drug from clinic to launch can take 6-10 years and often costs over $1 billion, before any sales start. That cash burn, plus GMP manufacturing and FDA work, is hard for small biotech entrants to fund, so competition enters slowly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeed for specialized expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. uses 3 proprietary formulation platforms, so a new entrant must master drug delivery science, not just make a pill or injection. That raises the entry bar: competitors need scientific, FDA, and go-to-market skill to match Xeris Biopharma Holdings, Inc.'s specialty focus across approved products like Gvoke and Recorlev.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMarket access is hard to win\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEven after approval, a new drug still has to win payer coverage, formulary placement, and physician trust. For Xeris Biopharma Holdings, Inc., that is a high bar because its markets depend on established wholesaler, specialty pharmacy, and prescriber ties that are slow and costly to copy.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eApproval does not equal access\u003c\/li\u003e\n\u003cli\u003ePayers can block uptake\u003c\/li\u003e\n\u003cli\u003eChannel ties take years to build\u003c\/li\u003e\n\u003cli\u003eThat raises entry risk for Xeris\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLow to moderate threat of entrants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. faces a low to moderate threat of new entrants because biotech startups can form, but FDA review, clinical trials, and manufacturing scale make fast entry hard. New drug development often takes 10 to 15 years and can cost more than $1 billion, which screens out most small players.\u003c\/p\u003e\n\u003cp\u003eLarger pharma firms can enter adjacent niches, but they still need time, payers, and distribution access, so the barrier is not easy to clear. In 2025, Xeris Biopharma Holdings, Inc. still benefited from this gap, since commercialization hurdles protect established products more than early science does.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulation slows entry\u003c\/li\u003e\n\u003cli\u003eCapital needs stay high\u003c\/li\u003e\n\u003cli\u003eCommercial launch is hard\u003c\/li\u003e\n\u003cli\u003eOverall threat: low to moderate\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Entry Risk for Xeris Biopharma Amid Costly, Slow Drug Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of new entrants for Xeris Biopharma Holdings, Inc. is low. In 2025, the FDA approved 50 new drugs, but getting there still takes 6-10 years and often more than $1 billion, plus GMP, payer, and launch hurdles. Xeris Biopharma Holdings, Inc.'s proprietary delivery platforms and specialty channels make entry even harder.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBarrier\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA approvals\u003c\/td\u003e\n\u003ctd\u003e50 in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDev time\u003c\/td\u003e\n\u003ctd\u003e6-10 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235131662601,"sku":"xers-five-forces","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/xers-five-forces.webp?v=1785736479","url":"https:\/\/dcfanalyst.com\/products\/xers-five-forces","provider":"DCF Analyst","version":"1.0","type":"link"}